Zobrazeno 1 - 10
of 62
pro vyhledávání: ''
Publikováno v:
Diabetes
Individuals with type 1 diabetes have an impaired glucagon counterregulatory response to hypoglycemia. Sodium—glucose cotransporter (SGLT) inhibitors increase glucagon concentrations. We evaluated whether SGLT inhibition restores the glucagon count
Autor:
Margaret Wu, Aleksandr Petrov, Liangsu Wang, Yuyan Ding, Nina Xiaoyan Li, David E. Kelley, Ge Dai, Tamara Dlugos, Robert S. Sherwin, Harold B. Wood, Mark D. Erion, Liming Yang, Timothy J. Kowalski, Stacey N. Brown
Publikováno v:
Diabetes. 67:1401-1413
Insulin-induced hypoglycemia in diabetes is associated with impaired glucagon secretion. In this study, we tested whether stimulation of GPR119, a G-protein–coupled receptor expressed in pancreatic islet as well as enteroendocrine cells and previou
Autor:
Armand Mbanya, Ilan Gabriely, Meredith Hawkins, Nora Tomuta, Akankasha Goyal, Eric Lontchi-Yimagou, Harry Shamoon, Michelle Carey, Oana A. Sandu, Rebekah Gospin, Raphael Hulkower
Publikováno v:
Diabetes
Although intensive glycemic control improves outcomes in type 1 diabetes mellitus (T1DM), iatrogenic hypoglycemia limits its attainment. Recurrent and/or antecedent hypoglycemia causes blunting of protective counterregulatory responses, known as hypo
Autor:
Hussein Al-Jobori, Muhammad A. Abdul-Ghani, John Adams, Robert A. Martinez, Curtis L Triplitt, Eugenio Cersosimo, Ali M. Ali, Ralph A. DeFronzo
Publikováno v:
Diabetes
The decrement in plasma glucose concentration with SGLT2 inhibitors (SGLT2i) is blunted by a rise in endogenous glucose production (EGP). We investigated the ability of incretin treatment to offset the EGP increase. Subjects with type 2 diabetes (n =
Autor:
Salvatore Calanna, Francesco Purrello, Jens J. Holst, Tina Vilsbøll, Filip K. Knop, Mette M. Rosenkilde, Alexander Hovard Sparre-Ulrich, Gerrit van Hall, Peter Lommer Kristensen, Jens Faber, Mikkel B. Christensen
Publikováno v:
Diabetes. 64:72-78
Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic, and glucagon-like peptide-1 (GLP-1) is glucagonostatic. We studied the effects of GIP and GLP-1 on glucagon responses to insulin-induced hypoglycemia in patients with type 1 diabe
Autor:
Dario Giugliano, Antonio Ceriello, Emilio Ortega, Gemma Pujadas, Anna Rita Bonfigli, Lucia La Sala, Anna Novials, Roberto Testa, Katherine Esposito
Publikováno v:
Diabetes
Currently there is debate on whether hypoglycemia is an independent risk factor for atherosclerosis, but little attention has been paid to the effects of recovery from hypoglycemia. In normal control individuals and in people with type 1 diabetes, re
Autor:
Patrizia Cioli, Geremia B. Bolli, Natalia Busciantella Ricci, Carmine G. Fanelli, Paolo Rossetti, Paola Candeloro, Francesca Porcellati
Publikováno v:
Diabetes. 57:746-756
OBJECTIVE—The acylated long-acting insulin analog detemir is more lipophilic than human insulin and likely crosses the blood-to-brain barrier more easily than does human insulin. The aim of these studies was to assess the brain/hypothalamus respons
Publikováno v:
Diabetes. 55:929-934
We hypothesized that increased capacity for brain utilization of nonglucose substrates (monocarboxylic acids [MCAs]) by upregulation of the MCA transporters may contribute metabolic substrates during hypoglycemia. To test this hypothesis, we assessed
Glucagon, Catecholamine, and Symptom Responses to Hypoglycemia in Living Donors of Pancreas Segments
Publikováno v:
Diabetes. 52:1689-1694
Donors undergoing hemi-pancreatectomy to provide a pancreas segment for transplantation into a relative with type 1 diabetes acquire diminished insulin and glucagon responses to intravenous agonists. Some donors develop diabetes and require treatment
Publikováno v:
Diabetes. 51:724-733
We tested the hypotheses that the glucagon response to hypoglycemia is reduced in patients who are approaching the insulin-deficient end of the spectrum of type 2 diabetes and that recent antecedent hypoglycemia shifts the glycemic thresholds for aut